Research programme: cancer therapeutics - Eternity Bioscience

Drug Profile

Research programme: cancer therapeutics - Eternity Bioscience

Alternative Names: Anaplastic lymphoma kinase inhibitors - Eternity Bioscience; BRAF inhibitors - Eternity Bioscience; BTK inhibitors - Eternity Bioscience; EBI 1041; EBI 2554; EBI-1051; EBI-1266; EBI-1367; EBI-907; EBI-945; MEK1 inhibitors - Eternity Bioscience; PARP-1/2 inhibitors - Eternity Bioscience; SHR-1266; TG-1702

Latest Information Update: 12 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eternity Bioscience
  • Class Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; EZH2 enzyme inhibitors; MAP kinase kinase 1 inhibitors; Poly(ADP-ribose) polymerase inhibitors; Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Breast cancer; Cancer; Ovarian cancer

Most Recent Events

  • 08 Jan 2018 EBI-1266 licensed to TG Therapeutics worldwide, excluding Asia but including Japan
  • 08 Jan 2018 Jiangsu Hengrui Medicine intends to file an IND application with the US FDA in the first half of 2018
  • 23 Sep 2016 Cancer therapeutics - Eternity Bioscience are available for licensing worldwide as of September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top